Biogen Inc (Biogen) is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson's disease, CNS and neuromuscular disorders, Alzheimer’s disease, and idiopathic pulmonary fibrosis and stroke. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Headquarters United States of America

Address 225 Binney Street, Cambridge, Massachusetts, 02142


Telephone 1 781 4642000

No of Employees 9,610

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange BIIB (NASD)

Revenue (2021) $11.0B -18.3% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -61.1% (2021 vs 2020)

Market Cap* $38.3B

Net Profit Margin (2021) XXX -52.4% (2021 vs 2020)

* As of and is in US$

Access premium data and analytics for Biogen Inc

650+

Clinical Trials

Determine Biogen Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

270+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

260+

Catalyst Calendar

Proactively evaluate Biogen Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

180+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Biogen Inc’s relevant decision makers and contact details.

170+

Pipeline Drugs

Identify which of Biogen Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Biogen Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

16+

Marketed Drugs

Understand Biogen Inc’s commercialized product portfolio to stay one step ahead of the market.

310+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

20+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

11+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

5

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Biogen Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Avonex: Alprolix
Multiple Sclerosis Avonex
Tysabri: Benepali
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Plans/Strategy In July, the company announced to evaluate litifilimab in systemic lupus erythematosus through the Phase 3 TOPAZ studies and plans to initiate a pivotal study in CLE.
2022 Regulatory Approval In July, the company and Eisai Co., Ltd announced the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab.
2022 Litigation In July, the company agreed to pay US$900 million to resolve claims brought by Michael Bawduniak.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Biogen Inc Johnson & Johnson Novartis AG Merck & Co Inc Bristol-Myers Squibb Co
Headquarters United States of America United States of America Switzerland United States of America United States of America
City Cambridge New Brunswick Basel Kenilworth New York
State/Province Massachusetts New Jersey - New Jersey New York
No. of Employees 9,610 141,700 108,000 68,000 32,200
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Stelios Papadopoulos, Ph.D. Chairman Executive Board 2014 72
Michel Vounatsos Chief Executive Officer; Director Executive Board 2017 59
Michael McDonnell Executive Vice President; Chief Financial Officer Senior Management 2020 58
Robin C. Kramer Chief Accounting Officer; Senior Vice President Senior Management 2020 56
Susan H. Alexander Secretary; Chief Legal Officer; Executive Vice President Senior Management 2011 65
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer